Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...
Pharmaceutical Technology6m
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
Asceneuron is the latest biotech to face setbacks in developing tau-targeting therapies for Alzheimer’s. After Eli Lilly and ...
This Once-Unstoppable Low-Cost Vanguard ETF Is Underperforming the S&P 500 in 2025. Here's Why It's a Buy Now.
The S&P 500 was down slightly year to date before last Friday's rally, which boosted the index into positive territory. Surprisingly, the Mega Cap Growth ETF is only down 1.5% year to date because ...
ENDPOINTS NEWS53m
In an un­usu­al move, Lil­ly seeks pitch­es from US states for slice of $27B build­out
Eli Lilly opens unprecedented public submission process for US states to pitch potential manufacturing sites as part of $27B ...
Investing Snacks42m
Eli Lilly: Billionaires’ Top Pick for 2025 Growth
Eli Lilly remains a favorite among billionaires, ranking 11th in top stock picks. The pharmaceutical giant’s 2024 revenue ...